

Disclaimer :

The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudices the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.

M.9274 • GLAXOSMITHKLINE / PFIZER CONSUMER HEALTHCARE BUSINESS

SECTION 1.2

Description of the concentration

1. On 19 December 2018, GlaxoSmithKline plc. ("**GSK**") and Pfizer, Inc. ("**Pfizer**") announced that each of GSK and Pfizer will contribute their respective consumer healthcare businesses to a new venture, over which GSK will have sole control.
2. GSK is active worldwide in the research, development, manufacturing, and marketing of prescription pharmaceuticals, vaccines and through its consumer healthcare business in worldwide research, development, manufacturing, and marketing of consumer healthcare pharmaceuticals, which are typically available without prescription (i.e., OTC), for various indications.

Pfizer's Consumer Healthcare business develops, manufactures and markets non-prescription medicines, vitamins and nutritional products globally.

Commission européenne, DG COMP MERGER REGISTRY, 1049 Bruxelles, BELGIQUE
Europese Commissie, DG COMP MERGER REGISTRY, 1049 Brussel, BELGIË

Tel: +32 229-91111. Fax: +32 229-64301. E-mail: COMP-MERGER-REGISTRY@ec.europa.eu.